HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 2, 2005, Pages 103-115

  Bussmann, Hermann ^a   Novitsky, Vladimir ^b   Wester, William ^a   Peter, Trevor ^a   Masupu, Kereng ^c   Gabaitiri, Lesego ^d,e   Kim, Soyeon ^a,e   Gaseitsiwe, Simane ^a   Ndung'u, Thumbi ^a   Marlink, Richard ^b   Thior, Ibou ^a   Essex, Max ^b  

^a BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^b Harvard AIDS Institute   (United States)

^c National AIDS Coordinating Agency   (Botswana)

^d UNIVERSITY OF BOTSWANA   (Botswana)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ARV drug resistance; Genotype polymorphisms; HIV 1 subtype C; Sub Saharan Africa (Botswana)

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BLOOD DONOR; BOTSWANA; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOSAICISM; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; STRUCTURAL GENE; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; DRUG EFFECT; MOLECULAR GENETICS; MUTATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BOTSWANA; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; POLYMORPHISM, GENETIC;

EID: 23244462809     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600203     Document Type: Article

References (39)

1. Adje-Toure C, Celestin B, Hanson D, Rods TH, Hertogs K, Larder B, Diomande F, Peelers M, Eholie S, Lackritz, E, Chorba T & Nkengasong JN (2003) Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rehound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire. AIDS 17(Suppl 3):S23-29.
2. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R & Rizzo C (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing non-nuclcoside reverse transcnptase inhibitor therapy. Journal of Virology 75:4999-5008.
3. Bennett DE, Zaidi IF, Heneinc W, Woods T, Garcia-Lerma JG, Smith AJ, McCormick I, & Weinstock HS (2003) Prevalence of mutations associated with antiretroviral drug resistance among men and women newly diagnosed with HIV in 10 US cities, 1997-2001. Antiviral Therapy 8:S134.
4. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N & Markowitz M (1999) HIV-1 drug resistance in newly infected individuals. Journal of the American Medical Association 282:1135-1141.
5. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M & Wamberg MA (2003) A V106M mutation m HIV-1 cladc C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-5.
6. Briones C, Perez-Olmeda M, Rodnguez C, del Romero J, Hertogs K & Soriano V (2001) Primary gcnotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. Journal of Acquired Immune Deficiency Syndromes 26:145-150.
7. Chaix ML, Descamps D, Mouajjah S, Deveau C, André P, Cottalorda J, Ingrand D, Izopet J, Kohli E, Masqelier B, Parmentier K, Poggi C, Rogez S, Ruffault A, Schneider V, Schmück A, Tamalet C, Wirden M, Rouzioux C, Meyer L, Brun-Vézinet F, Costagliola D & the ANRS AC11 Resistance Group, Cohort PRIMO, INTERPRIM and PRIMSTOP Study Groups (2003) French National Sentinel Survey of antiretroviral resistance in patients with HIV-1 primary infection and m antiretroviralnaive chronically infected patients in 2001-2002. Antiviral Therapy 8(S137): Abstract 123.
8. Descamps D, Calvez V, Izopet J, Buffet-Janvresse C, Schmück A, Colson P, Ruffault A, Maillard A, Masquelier B, Cottalorda J, Harzic M, Brun-Vézinet F, & Costagliola D; ANRS Antiretroviral Resistance Study Group (2001) Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study. AIDS 15:1777-1782.
9. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, Weber JN ScMcClure MO (2001) Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 15:1493-1502.
10. Geretti AM, Smith M, Osner N, O'Shea S, Chrystie I, Easterbrook P & Zuckerman M (2001) Prevalence of antiretroviral resistance m a South London cohort of treatment-naive HIV-1-infected patients. AIDS 15:1082-1084.
11. Geretti AM, Smith M, Watson C, Mullen J, Osner N, O'Shea S, Chrystie I, Zuckerman M & Easterbrook P (2002) Primary antiretroviral resistance in newly diagnosed patients with established heterosexually acquired HIV-1. AIDS 16:2358-2360.
12. Gordon M, De Oliveira T, Bishop K, Coovadia HM, Madurai L, Engelbrecht S, Janse van Rensburg E, Mosam A, Smith A & Cassol S (2003) Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. Journal of Virology 77:2587-2599.
13. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, Burke M, Gottesman G, Istomin V, Levi I, Maayan S, Shahar E & Schapiro JM; Israel Multi-Center Study Group (2001) Genotypic variation of HIV-1 reverse transcnptase and protease: comparative analysis of clade C and clade B. AIDS 15:1453-1460.
14. Handema R, Terunuma H, Kasolo F, Kasai H, Sichone M, Yamashita A, Deng X, Mulundu G, Ichiyama K, Munkanta M, Yokota T, Wakasugi N, Tezuka F, Yamamoto N & Ito M (2003) Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Research & Human Retroviruses 19:151-160.
15. Havlir D, Vella S, & Hammer S (2002) The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society. AIDS 16:7-9.
16. Jayaraman GC, Gleeson T, Sandstrom P & Archibald CP (2003) The Canadian HIV Strain and Drug Resistance Program-a population-based effort to enhance HIV surveillance. Antiviral Therapy 8:S135.
17. Kantor R, Zijenah LS, Shafer RW, Mutetwa S, Johnston E, Lloyd R, von Lieven A, Israelski D, & Katzcnstein DA (2002) HIV-1 subtype C reverse transcnptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Research & Human Retro-viruses 18:1407-1413.
18. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS & Richman DD (2002) Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine 347:385-394.
19. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M & Wainberg MA (2002) Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrobial Agents & Chemotherapy 46:2087-2094.
20. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW & St Ray SC (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-mfected seroconverters in India, with evidence of intersubtype recombination. Journal of Virology 73:152-160.
21. Montano MA, Nixon CP & Essex M (1998) Dysregulation through the NF-kappaB enhancer and TATA box of the human immunodeficiency virus type 1 subtype E promoter. Journal of Virology 72:8446-8452.
22. Montano MA, Nixon CP, Ndung'u T, Bussmann H, Novitsky VA, Dickman D & St Essex M (2000) Elevated tumour necrosis factoralpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. Journal of Infectious Diseases 181:76-81.
23. Montano MA, Novitsky VA, Blackard JT, Cho NL, Katzenstein DA & Essex M (1997) Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. Journal of Virology 71:8657-8665.
24. NACA (2003) Botswana 2003 Second Generation HIV/AIDS Surveillance. A Technical Report. Gaborone: National AIDS Coordinating Agency.
25. Ndung'u T, Renjifo B, Novitsky VA, McLane MF, Gaolekwe S & Essex M (2000) Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. Virology 278:390-399.
26. Novitsky VA, Gaolekwe S, McLane MF, Ndung'u TP, Foley BT, Vannberg F, Marlink R & Essex M (2000) HIV type 1 A/J recombinant with a pronounced pol gene mosaicism. AIDS Research & Human Retro-viruses 16:1015-1020.
27. Novitsky VA, Montano MA, McLane MF, Renjifo B, Vannberg F, Foley BT, Ndung'u TP, Rahman M, Makhema MJ, Marlink R & Essex M (1999) Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. Journal of Virology 73:4427-4432.
28. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, Ndung'u T, Klein I, Chang SY, Peter T, Thior I, Foley BT, Gaolekwe S, Rybak N, Gaseitsiwe S, Vannberg F, Marlink R, Lee TH & Essex M (2002) Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? Journal of Virology 76:5435-5451.
29. Perno CF, Cozzi-Lepri A, Balotta C, Bertoli A, Violin M, Monno L, Zauli T, Montroni M, Ippolito G & d'Arminio-Monforte A; ICONA Study Group (2002) Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS 16:619-624.
30. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D & Routy JP (2000) Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14:F17-23.
31. Shafer RW (2002) Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clinical Microbiology Reviews 15:247-277.
32. Shafer RW, Eisen JA, Merigan TC & Katzenstein DA (1997) Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Journal of Virology 71:5441-5448.
33. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F & Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Research 25:4876-4882.
34. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance (2001) Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. British Medical Journal 322:1074-1075.
35. Van Vaerenbergh K, Debaisieux L, De Cabooter N, Declercq C, Desmet K, Fransen K, Maes B, Marissens D, Miller K, Muyldermans G, Sprecher S, Stuyver L, Vaira D, Verhofstede C, Zissis G, Van Ranst M, De Clercq E, Desmyter J & Vandamme AM (2001) Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium. Antiviral Therapy 6:63-70.
36. Velazquez-Campoy A, Vega S ocFreire E (2002) Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 41:8613-8619.
37. Vergne L, Kane CT, Laurent C, Diakhate N, Gueye NF, Gueye PM, Sow PS, Paye MA, Liegeois F, Ndir A, Laniece I, Peeters M, Ndoye I, Mboup S & Delaporte E (2003) Low rate of genotypic HIV-I drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 17(Suppl 3):S31-38.
38. Wainberg, MA & Friedland G (1998) Public health implications of antiretroviral therapy and HIV drug resistance. Journal of the American Medical Association 279:1977-1983.
39. Yerly S, Kaiser L, Race E, Bru JP, Clavel F & Perrin L (1999) Transmission of antiretroviral drug-resistant HIV-1 variants. Lancet 354:729-733.